ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0640

7000-Plex Proteomic Screen of Urine for Flare Monitoring and Treatment Response Biomarkers in Active Lupus Nephritis
Abstract Number: 0641

Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Abstract Number: 0642

Anti-Myxovirus Resistance Protein 1: A Novel Biomarker for Autoimmune Myositis and Interstitial Lung Disease in Systemic Lupus Erythematosus
Abstract Number: 0643

Using FDG PET Brain Scans and Deep Learning Analyses to Identify a Specific Network Correlated with Cognitive Impairment in SLE
Abstract Number: 0644

Scoping Literature Review to Identify Candidate Domains for the SLE OMERACT Core Outcome Set
Abstract Number: 0645

Mortality and Ethnicity in Adults with Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Analysis
Abstract Number: 0646

Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations
Abstract Number: 0647

Clinical Associations and Outcomes of Pericarditis in Systemic Lupus Erythematosus
Abstract Number: 0648

Prevalence of Pulmonary Complications Among Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Meta-analysis
Abstract Number: 0649

Urinary Acetylated Albumin as a Biomarker of Nephritis in Patients with Systemic Lupus Erythematosus
Abstract Number: 0650

Tubulointerstitial Inflammation Predicts Tubular Atrophy, Fibrosis, and Renal Function Loss in Lupus Nephritis
Abstract Number: 0651

Renal Survival and Mortality in Patients with Proliferative and Membranous Lupus Nephritis
Abstract Number: 0652

Analysis of Relapses in a Single Center Cohort of Patients with Lupus Nephritis
Abstract Number: 0653

Impact of Lupus Nephritis on Neuropsychiatric SLE Outcomes
Abstract Number: 0654

Corneal Confocal Microscopy: An Ophthalmic Imaging Biomarker for Small Fiber Neuropathy in Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].